137 related articles for article (PubMed ID: 22303338)
1. Peripheral blood RNA expression profiling in illicit methcathinone users reveals effect on immune system.
Sikk K; Kõks S; Soomets U; Schalkwyk LC; Fernandes C; Haldre S; Aquilonius SM; Taba P
Front Genet; 2011; 2():42. PubMed ID: 22303338
[TBL] [Abstract][Full Text] [Related]
2. A Parkinsonian syndrome in methcathinone users and the role of manganese.
Stepens A; Logina I; Liguts V; Aldins P; Eksteina I; Platkājis A; Mārtinsone I; Tērauds E; Rozentāle B; Donaghy M
N Engl J Med; 2008 Mar; 358(10):1009-17. PubMed ID: 18322282
[TBL] [Abstract][Full Text] [Related]
3. Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome.
Juurmaa J; Menke RA; Vila P; Müürsepp A; Tomberg T; Ilves P; Nigul M; Johansen-Berg H; Donaghy M; Stagg CJ; Stepens A; Taba P
Brain Behav; 2016 Nov; 6(11):e00539. PubMed ID: 27843694
[TBL] [Abstract][Full Text] [Related]
4. The outcome of the movement disorder in methcathinone abusers: clinical, MRI and manganesemia changes, and neuropathology.
Stepens A; Groma V; Skuja S; Platkājis A; Aldiņš P; Ekšteina I; Mārtiņsone I; Bricis R; Donaghy M
Eur J Neurol; 2014 Feb; 21(2):199-205. PubMed ID: 23678867
[TBL] [Abstract][Full Text] [Related]
5. Urine as a material for evaluation of exposure to manganese in methcathinone users.
Golasik M; Wodowski G; Gomółka E; Herman M; Piekoszewski W
J Trace Elem Med Biol; 2014 Jul; 28(3):338-43. PubMed ID: 24867657
[TBL] [Abstract][Full Text] [Related]
6. Subacute administration of both methcathinone and manganese causes basal ganglia damage in mice resembling that in methcathinone abusers.
Asser A; Hikima A; Raki M; Bergström K; Rose S; Juurmaa J; Krispin V; Muldmaa M; Lilles S; Rätsep H; Jenner P; Kõks S; Männistö PT; Taba P
J Neural Transm (Vienna); 2020 May; 127(5):707-714. PubMed ID: 31786692
[TBL] [Abstract][Full Text] [Related]
7. Manganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up.
Sikk K; Haldre S; Aquilonius SM; Asser A; Paris M; Roose Ä; Petterson J; Eriksson SL; Bergquist J; Taba P
Eur J Neurol; 2013 Jun; 20(6):915-20. PubMed ID: 23347399
[TBL] [Abstract][Full Text] [Related]
8. Methcathinone "Kitchen Chemistry" and Permanent Neurological Damage.
Sikk K; Taba P
Int Rev Neurobiol; 2015; 120():257-71. PubMed ID: 26070761
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood RNA gene expression profiling in patients with bacterial meningitis.
Lill M; Kõks S; Soomets U; Schalkwyk LC; Fernandes C; Lutsar I; Taba P
Front Neurosci; 2013; 7():33. PubMed ID: 23515576
[TBL] [Abstract][Full Text] [Related]
10. Manganese Encephalopathy Caused by Homemade Methcathinone (Ephedrone) Prevalence in Poland.
Habrat B; Silczuk A; Klimkiewicz A
Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684497
[TBL] [Abstract][Full Text] [Related]
11. Methcathinone: a new postindustrial drug.
Belhadj-Tahar H; Sadeg N
Forensic Sci Int; 2005 Oct; 153(1):99-101. PubMed ID: 15919169
[TBL] [Abstract][Full Text] [Related]
12. [Encephalopathy caused by intravenous potassium permanganate used for illegal production of methcathinone (ephedrone) from medicines containing pseudoephedrine].
Habrat B; Baran-Furga H; Sienkiewicz-Jarosz H; Sein Anand J; Poniatowska R
Przegl Lek; 2013; 70(8):613-6. PubMed ID: 24466704
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs.
Wu JQ; Saksena MM; Soriano V; Vispo E; Saksena NK
Virol J; 2015 Jan; 12():4. PubMed ID: 25623235
[TBL] [Abstract][Full Text] [Related]
14. Manganese Encephalopathy among Ephedron Abusers.
Janocha-Litwin J; Marianska K; Serafinska S; Simon K
J Neuroimaging; 2015; 25(5):832-5. PubMed ID: 25255816
[TBL] [Abstract][Full Text] [Related]
15. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428.
McCann UD; Wong DF; Yokoi F; Villemagne V; Dannals RF; Ricaurte GA
J Neurosci; 1998 Oct; 18(20):8417-22. PubMed ID: 9763484
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of methcathinone and manganese in mice: A dose response study.
Asser A; Kõks S; Soomets U; Terasmaa A; Sauk M; Eltermaa M; Piip P; Ubhayasekera K; Bergquist J; Taba P
Heliyon; 2019 Sep; 5(9):e02475. PubMed ID: 31687570
[TBL] [Abstract][Full Text] [Related]
17. Increased striatal VMAT2 binding in mice after chronic administration of methcathinone and manganese.
Asser A; Kõks S; Snellman A; Haaparanta-Solin M; Arponen E; Grönroos T; Nairismägi J; Bergquist J; Soomets U; Piip P; Eltermaa M; Sauk M; Lindmäe H; Rinne JO; Taba P
Brain Res; 2016 Dec; 1652():97-102. PubMed ID: 27693414
[TBL] [Abstract][Full Text] [Related]
18. Intravenous self-injection of methcathinone in the baboon.
Kaminski BJ; Griffiths RR
Pharmacol Biochem Behav; 1994 Apr; 47(4):981-3. PubMed ID: 8029273
[TBL] [Abstract][Full Text] [Related]
19. [Cognitive dysfunctions caused by excessive exposure to manganese compounds. Cognitive disturbances in intravenous users of ephedrone (methcathinone) with manganese compounds].
Kałwa A; Habrat B
Psychiatr Pol; 2015; 49(2):305-14. PubMed ID: 26093594
[TBL] [Abstract][Full Text] [Related]
20. Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism.
Djamshidian A; Sanotsky Y; Matviyenko Y; O'Sullivan SS; Sharman S; Selikhova M; Fedoryshyn L; Filts Y; Bearn J; Lees AJ; Averbeck BB
Addiction; 2013 Apr; 108(4):771-9. PubMed ID: 23228208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
